reports
- Emmanuel Matot
MMK MAYR-MELNHOF KARTON AG
PNL POSTNL NV
NEX NEXANS SA
MIL BANK MILLENNIUM SA
ADVI ADVINI
SOI SOITEC SA
PAL PALFINGER AG
SZU SUEDZUCKER AG
MMT METROPOLE TELEVISION SA
DLG DE'LONGHI S.P.A.
CIE CIE AUTOMOTIVE S.A.
NOD NORDIC SEMICONDUCTOR ASA
CASH PROSEGUR CASH SA
2CRSI 2CRSI SA
ALHRS HYDROGEN REFUELING SOLUTIONS
XLS XLIFE SCIENCES AG
CAN CANAL+
- Emmanuel Matot
MMK MAYR-MELNHOF KARTON AG
PNL POSTNL NV
NEX NEXANS SA
MIL BANK MILLENNIUM SA
ADVI ADVINI
SOI SOITEC SA
PAL PALFINGER AG
SZU SUEDZUCKER AG
MMT METROPOLE TELEVISION SA
DLG DE'LONGHI S.P.A.
CIE CIE AUTOMOTIVE S.A.
NOD NORDIC SEMICONDUCTOR ASA
CASH PROSEGUR CASH SA
2CRSI 2CRSI SA
ALHRS HYDROGEN REFUELING SOLUTIONS
XLS XLIFE SCIENCES AG
CAN CANAL+
- Jacob Mekhael
Zealand Pharma Survodutide posts 16.6% weight loss, shows lean mass pr...
Zealand announced that its partner Boehringer Ingelheim has reported topline results from the phase 3 (SYNCHRONIZE-1) trial of survodutide (GLP-1/glucagon analog) in adults with overweight/obesity without T2D. The 16.6% weight loss at 76 weeks achieved with survodutide in the phase 3 trial appears lower than the 18.7% that the drug achieved in phase 2 at 46 weeks. This outcome places survodutide somewhere between semaglutide and tirzepatide when it comes to weight loss efficacy, however, we're i...
- ING Helpdesk
Benelux Morning Notes
Coca-Cola Europacific Partners: Easter bunny. dsm-firmenich: No Pin, No Gain. D'Ieteren: Belgian competitor Autoglass Clinic doubles in size since acquisition by Cary. PostNL: 1Q26 trading disappoints on weak volume trends; FY26 outlook reiterated. Theon International: Preview – up for a solid start
- Jacob Mekhael
- Michiel Declercq
- Wim Hoste
- Stefano Toffano
- Wim Gille
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 d...
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from base...
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 28, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 9 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 22, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand ...
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 21, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand ...
Zealand Pharma launches long-term incentive programs for Zealand Pharm...
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the “LTIP...
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Inves...
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henri...
- ING Helpdesk
Benelux Morning Notes
Belfius: strategy 2030 vs FY25 results: acceleration to +5% CAGR. dsm-firmenich: Givaudan 1Q26 trading update. D'Ieteren: Carglass's exclusive mobile ADAS calibration launch in France. EVS: €5m share buy-back programme. SBM Offshore: SEAP & Nigeria. Staffing sector: PageGroup 1Q26 trading update. TomTom: Preview 1Q26, no material changes expected. Zabka: 1Q26 Preview
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 14, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
- Marc Zwartsenburg
- CEFA
PostNL/2026 a transition year/HOLD
We keep our HOLD, raising our Target Price slightly from €0.95 to €1.00 to reflect the incorporation of FY27 estimates. We have modelled in the new segmentation and our estimates are virtually unchanged. FY26 will be a transition year towards the D+2/D+3 mail delivery model and with letterbox parcels being transferred to the e-commerce segment as per 2H26. FY26 will thus involve some transition costs while the benefits from the new mail model will phase in gradually before becoming fully effecti...
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 7, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to cov...
- ING Helpdesk
Total number of shares and voting rights in Zealand Pharma as of March...
Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its ...
Weekly progress on share repurchase program to cover share plans and r...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), March 31, 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.